C

    Collplant Biotechnologies Ltd (CLGN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.39
    +0.03 (+8.35%)

    Market Cap: $7.33M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    21%(6/29)
    Avg Surprise
    -137.39%
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    Reported Aug 20
    		$-0.28$-0.24-16.67%Miss+0.0%
    Mar 26
    Reported May 29
    		$-0.23$-0.13-72.51%Miss-73.3%
    Dec 25
    Reported Mar 26
    		$-0.25$-0.19-31.58%Miss+24.2%
    Sep 25
    Reported Nov 26
    		$-0.27$0.16-268.75%Miss+28.9%
    Jun 25
    Reported Aug 20
    		$-0.28$-0.10-180.00%Miss+24.3%
    Mar 25
    Reported May 28
    		$-0.13$-0.04-225.00%Miss+64.9%
    Dec 24
    Reported Mar 26
    		$-0.33$-0.28-20.00%Miss-37.5%
    Sep 24
    Reported Nov 27
    		$-0.38$-0.28-35.71%Miss+0.0%
    Jun 24
    Reported Aug 20
    		$-0.37$-0.27-37.04%Miss-175.5%
    Mar 24
    Reported Apr 4
    		$-0.37$-0.35-5.71%Miss-12.1%
    Dec 23
    Reported Jan 25
    		$-0.24$-0.07-242.86%Miss+36.8%
    Sep 23
    Reported Nov 29
    		$-0.38$0.03-1366.67%Miss+5.0%
    Jun 23
    Reported Aug 24
    		$0.49$0.08+512.50%Beat+225.6%
    Mar 23
    Reported May 24
    		$-0.33$-0.39+15.38%Beat+8.3%
    Dec 22
    Reported Mar 29
    		$-0.38$-0.31-22.58%Miss-26.7%
    Sep 22
    Reported Dec 1
    		$-0.40$0.48-183.33%Miss-37.9%
    Jun 22
    Reported Aug 25
    		$-0.39$-0.08-387.50%Miss-30.0%
    Mar 22
    Reported May 26
    		$-0.36$-0.14-157.14%Miss-140.9%
    Dec 21
    Reported Mar 24
    		$-0.30$-0.29-3.45%Miss+28.6%
    Sep 21
    Reported Nov 18
    		$-0.29$-0.27-7.41%Miss-363.6%
    Jun 21
    Reported Aug 19
    		$-0.30$-0.27-11.11%Miss-50.0%
    Mar 21
    Reported May 27
    		$0.88$0.80+10.00%Beat+519.0%
    Dec 20
    Reported Mar 26
    		$-0.42$-0.30-40.00%Miss+51.2%
    Sep 20
    Reported Dec 1
    		$0.11N/A-94.39%Miss+126.8%
    Jun 20
    Reported Aug 28
    		$-0.20$-0.25+20.00%Beat-17.6%
    Mar 20
    Reported Apr 1
    		$-0.21N/A+53.33%Beat-2000.0%
    Dec 19
    Reported Mar 18
    		$-0.86$-0.07-1128.57%Miss-196.0%
    Sep 19
    Reported Nov 29
    		$-0.41$-0.26-57.69%Miss-7635.8%
    Jun 19
    Reported Sep 26
    		$-0.17$0.00N/ABeat-1923.8%
    Mar 19
    Reported Apr 1
    		$-0.01$-0.01+0.00%Beat+10.7%
    Dec 18
    Reported Mar 31
    		$-0.29$0.00N/ABeat+43.0%
    Sep 18
    Reported Nov 29
    		$-0.01N/AN/ABeat+33.8%
    Jun 18
    Reported Sep 21
    		$-0.01N/AN/ABeat+32.8%
    Mar 18
    Reported May 24
    		$-0.01N/AN/ABeat+5.1%
    Dec 17
    Reported Mar 21
    		$-0.51N/AN/ABeat-2864.0%
    Sep 17
    Reported Nov 20
    		$-0.01N/AN/ABeat+84.2%
    Jun 17
    Reported Sep 1
    		$-0.01N/AN/ABeat-
    Mar 17
    Reported May 29
    		$-0.01N/AN/ABeat-
    Dec 16
    Reported Mar 27
    		$-0.02N/AN/ABeat-
    Sep 16
    Reported Nov 24
    		$-0.05N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.38EV/EBITDA-5.97x
    Price/FCF-0.46xFCF Yield-217.57%
    Profitability
    Profit Margin0.00%Operating Margin-4267.00%
    ROE-152.00%ROIC-179.53%
    Financial Health
    Debt/Equity0.16xInterest CoverageN/A
    Current Ratio2.27xQuick Ratio1.99x
    Trading Statistics
    Beta0.68Avg Volume9.09M
    52-Week High$3.1852-Week Low$0.26

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.32
    SMA 20$0.32
    SMA 50$0.33
    SMA 200$0.81
    EMA 10$0.33
    EMA 20$0.32
    EMA 50$0.34
    EMA 200$0.82

    MACD

    Line: 0.00Signal: -0.00Hist: 0.01

    ADX

    ADX: 16.3+DI: 58.7-DI: 5.4

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down96.0
    PSAR$0.26

    Bollinger Bands

    Upper Band$0.37
    Lower Band$0.27
    %B Position3002%(Upper)
    Band Width1.22

    RSI (14-Day)

    Neutral
    63.4

    Momentum Oscillators

    Stoch %K32.4
    Stoch %D32.1
    Williams %R-82.2
    ROC (10d)21.3%
    Momentum0.07
    CCI (20d)604.7
    MFI (14d)99.8

    Volatility Measures

    ATR (14d)$0.08(21.5%)
    StdDev (20d)0.02
    Hist Vol121.1%(High)

    Volume Flow

    VWAP$0.57
    OBV183.9M
    AD Line-160.3M
    CMF (20d)-0.849

    Volume Metrics

    Avg Vol (20d)9.5M
    Vol Ratio18.9x(High)
    VWMA (20d)$0.39

    Pivot Points

    R3$0.57
    R2$0.49
    R1$0.43
    Pivot Point$0.34
    S1$0.28
    S2$0.20
    S3$0.13

    Advanced Oscillators

    TSI2.06
    Ultimate Osc24.1
    KST-23.17

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$73,000$60,000$77,000$179,000$2.06M$164,000$4,000$249,000$98,000$299,000$43,000$10.18M
    Cost of Revenue$316,000$408,000$492,000$415,000$432,000$514,000$527,000$797,000$825,000$773,000$550,000$881,000
    Gross Profit$-243,000$-348,000$-415,000$-236,000$1.62M$-350,000$-523,000$-548,000$-727,000$-474,000$-507,000$9.30M
    Operating Expenses$2.87M$2.80M$3.09M$2.94M$3.27M$3.62M$4.02M$3.86M$3.60M$5.37M$4.09M$3.63M
    R&D$1.68M$1.98M$2.09M$2.01M$2.10M$2.54M$2.87M$2.70M$2.41M$3.11M$2.69M$2.57M
    SG&A$1.19M$1.04M$1.23M$1.16M$1.41M$1.32M$1.41M$1.42M$1.48M$1.48M$1.67M$1.32M
    Operating Income$-3,115,000$-3,150,000$-3,507,000$-3,178,000$-1,648,000$-3,974,000$-4,542,000$-4,406,000$-4,329,000$-5,068,000$-4,602,000$5.68M
    Interest Income$0$329,000$24,000$0$0$192,000$216,000$0$0$0$225,000$0
    Interest Expense$0$57,000$0$169,000$0$17,000$0$0$10,000$0$0$0
    Income Before Tax$-3,097,000$-3,207,000$-3,483,000$-3,347,000$-1,452,000$-3,878,000$-4,326,000$-4,210,000$-4,195,000$-4,689,000$-4,377,000$5.76M
    Income Tax Expense$0$0$0$0$0$0$0$0$-1$0$311,586$143,915
    Net Income$-3,097,000$-3,207,000$-3,483,000$-3,347,000$-1,452,000$-3,878,000$-4,326,000$-4,210,000$-4,195,000$-4,689,000$-4,377,000$5.76M
    EBITDA$-2,887,000$-2,934,000$-3,260,000$-2,949,000$-1,208,000$-3,636,000$-4,071,000$-3,949,000$-3,915,000N/A$-4,105,000$6.03M
    EBIT$-3,097,000$-3,150,000$-3,483,000$-3,178,000$-1,452,000$-3,878,000$-4,326,000$-4,210,000$-4,195,000N/A$-4,377,000$5.76M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CLGN

    News

    CollPlant Shareholders Approve All Proposals at August 18 Extraordinary Meeting

    CollPlant Biotechnologies Ltd. shareholders approved all proposals at their Extraordinary General Meeting on August 18, 2026, reinforcing the company's adherence to U.S. securities regulations for financing and employee compensation. Despite this, TipRanks' AI Analyst "Spark" rates CLGN as "Underperform" due to weak financial performance and a persistent downtrend in its stock. The company, based in Israel, maintains its U.S. regulatory presence to access global investors.

    The Globe and Mail•8/20/26•
    Bearish

    CollPlant (CLGN) shareholders back both August EGM items

    CollPlant Biotechnologies Ltd. (CLGN) announced that its shareholders approved both proposals presented at an Extraordinary General Meeting (EGM) held on August 18, 2026. The company's Form 6-K report, detailing the EGM outcome, is incorporated by reference into its existing Form S-8 and Form F-3 registration statements. This ensures the information becomes part of the official registration documents for securities law purposes.

    Stock Titan•8/19/26•
    Neutral

    CollPlant Biotechnologies (CLGN) lifts share capital, files new resale opinion

    CollPlant Biotechnologies (CLGN) reported that its shareholders approved an increase in authorized share capital from 30 million to 500 million ordinary shares, each with a par value of NIS 1.50. Following this approval, the company filed an updated legal opinion concerning the validity of ordinary shares registered for resale under its Form F-3 Registration Statement. This filing and its exhibits are incorporated by reference into the said registration statement.

    Stock Titan•8/6/26•
    Neutral

    CollPlant Shareholders Approve Proposal at Extraordinary General Meeting

    CollPlant Biotechnologies held an Extraordinary General Meeting of Shareholders in Israel on July 29, 2026, where shareholders approved the single proposal presented in the company’s July 7, 2026 notice. This approval formalizes the company's intended corporate action and integrates the outcome into its U.S. registration statements. While analysts have a "Buy" rating with an $11.00 price target for CLGN stock, TipRanks’ AI Analyst, Spark, assesses CLGN as "Neutral" due to weak financial performance and a clear downtrend.

    The Globe and Mail•7/30/26•
    Neutral

    CollPlant Biotechnologies (CLGN) investors approve EGM proposal

    CollPlant Biotechnologies Ltd. (CLGN) announced that its shareholders approved a proposal at an Extraordinary General Meeting (EGM) held on July 29, 2026. The proposal, detailed in a notice dated July 7, 2026, was approved by the required majority. This report is incorporated by reference into the company's existing Registration Statements on Form S-8 and Form F-3.

    Stock Titan•7/30/26•
    Neutral

    Frequently Asked Questions About CLGN

    Does CLGN pay dividends?
    Collplant Biotechnologies Ltd (CLGN) does not currently pay a regular dividend.
    What is CLGN's market cap?
    Collplant Biotechnologies Ltd (CLGN) has a market capitalization of $7.33M with a current stock price of $0.39.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In